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Inflammation is a marker of arterial disease stemming from cholesterol-dependent to -independent 
molecular mechanisms. In recent years, the role of inflammation in atherogenesis has been 
underpinned by pharmacological approaches targeting systemic inflammation that have led to a 
significant reduction in cardiovascular (CV) risk. Although the use of nutraceuticals to prevent CV 
disease has largely focused on lipid-lowering (e.g, red-yeast rice and omega-3 fatty acids), there is 
growing interest and need, especially now in the time of coronavirus pandemic, in the use of 
nutraceuticals to reduce inflammatory markers, and potentially inflammatory CV burden, however 
we have not still had enough data to confirm this. Indeed, diet is an important lifestyle determinant 
of health and can influence both systemic and vascular inflammation, to varying extents, according 
to the individual nutraceutical constituents. Thus, the aim of this Position Paper is to provide the 
first attempt at recommendations on the use of nutraceuticals with effective anti-inflammatory 
properties. 
 
Keywords: cardiovascular disease, C-reactive protein, inflammation, nutraceuticals, omega-3, 
position paper, red-yeast rice. 
 

















Overactivation of the inflammation cascade is a well-established factors promoting tissue and 
organ disfunction in several disease conditions [1,2]. Increasingly clear evidence demonstrates 
additional roles for inflammation in the development of arterial diseases [1,2]. Inflammation is, in 
fact, an obligatory marker of atherosclerotic cardiovasculr disease (ASCVD), resulting from the 
inflammatory activity of cholesterol itself as well as from other well-established molecular 
mechanisms [1]. Clinical trials with anti-inflammatory drugs have led to the extensive evaluation of 
biomarkers, such as high sensitivity C-reactive protein (hsCRP) and interleukin (IL)-6, which are 
indicative of raised cardiovascular (CV) risk [2]. The approach to the prevention of atherosclerosis 
increasingly encompasses the targeting of inflammation [3] and the increased use of agents 
targeting inflammatory pathways [4]. 
Since inflammation scontribute to residual CV risk after optimal preventive treatments with, 
e.g. statins, the mechanisms of the inflammatory process have been studied in detail. In terms of 
molecular mechanisms, cholesterol crystals in atherosclerotic lesions can promote plaque instability 
[5] by activation of NLR family pyrin domain containing 3 (NLRP3) (NACHT-, LRR- and pyrin domain-
containing 3). NLRP3 nucleates the assembly of an inflammasome, leading to caspase 1-mediated 
activation of the interleukin-1β (IL-1β) family of cytokines, thus inducing inflammatory pyroptotic 
cell death [6]. More recently, the study of mechanisms related to myelopoiesis [7] has led to 
important contributions to the understanding of inflammatory mechanisms underlying acute 
coronary syndromes (ACS) and of potentially protective mechanisms such as Tet methylcytosine 
dioxygenase 2 (TET2) production [8]. In addition to drugs specifically affecting this pathway (e.g. 
canakinumab and colchicine), anti-inflammatory actions of agents in general use in CV prevention, 
e.g., statins, have become widely known (11). In line with this evidence, there is also a growing 
interest in non-drug, natural products (nutraceuticals) approaches to the inflammatory etiology of 
CVD [9]. The use of nutraceuticals to help to prevent CVD has largely focused on lipid-lowering to 
date, such as in the highly detailed documents produced by the International Lipid Expert Panel 
(ILEP) [10]. This work, however, has highlighted the potential of these agents to effect inflammatory 
parameters, and in the consequence their potential to play a supplemental role in the reduction of 






In order to provide an objective assessment of nutraceuticals with a potential anti-
inflammatory activity, the purpose of this Position Paper is to classify nutraceuticals by molecular 
type and mechanism of action. This will allow us to highlight the most important recent 
developments in this therapeutic area and to recommend the nutraceuticals with the largest 
potential based on the available evidences.  
To pursue this aim, the following search algorithm was used to search pubmed.gov (by 31st 
March 2021): nutraceuticals OR nutraceutical approaches OR absorbable nutraceuticals OR non-
absorbable nutraceuticals AND inflammation AND atherosclerosis AND cardiovascular disease. 
Relevant in vitro, in vivo and clinical studies were included in this review.  
The levels of evidence and the strength of recommendation have been weighed and graded 
according to predefined scales, as outlined in Tables 1 and 2. The experts of the recomemndations, 
based on available data, extensively discussed each nutraceutical finally included in the Position 
Paper and discussed and agreed on the recommended levels. Due to the fact of the limited data the 
experts did not decide to evaluate each selected nutraceutical with the class of the evidence. The 
experts of the writing and reviewing panels completed declaration of interest forms where real or 
potential sources of conflicts of interest might be perceived (at the end of the paper). 
Physicians and medical professionals of other specialties treating patients with inflammatory 
conditions are encouraged to consider the Position Paper in the process of evaluating the clinical 
status of their patients and to determine and implement medical strategies with the recommended 
nutraceuticals. However, the Position Paper does not override in any way the individual 
responsibility of physicians to make appropriate and accurate decisions taking into account the 
condition of a given patient and in consultation with that patient, and, where necessary, with the 
patient’s guardian or caretaker. It is also the responsibility of health professionals to verify the 
doses, rules, and regulations applicable to drugs and devices at the time of their prescription/use.  
 
DIETARY COMPONENTS, NUTRACEUTICALS AND ANTI-INFLAMMATORY PROPERTIES 
Diet is an important lifestyle determinant of health and can influence inflammation, including 
vascular inflammation, to varying extents, according to the individual components of food [14]. 
Among food-components with a drug-like activity, commonly used nutraceuticals play a major role. 
A nutraceutical, as per the definition by De Felice (1989), “is a food or part of a food, providing a 
medical or health benefit. These products may range from isolated nutrients to dietary supplements 
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and specific diets to genetically engineering designed foods, herbal products and processed foods”. 
It has become customary, in daily practice, to distinguish between nutraceuticals with 
pharmaceutical-like formulations, in which the composition is standardized, and “functional foods”, 
i.e., foods with health benefits [13,14]. 
 
Omega- 6 fatty acids 
Dietary fatty acids, in particular, omega-6 fatty acids, are major components of daily lipid intake. 
The predominant polyunsaturated fatty acid (PUFA) is linoleic acid (LA:18:2 n-6), whose intake has 
been associated, in a number of epidemiological and interventional studies, with reduced CV risk 
[11, 12]. A recent assessment of omega-6 PUFA intake among adults in the UK indicated an intake 
of 10.9±4.7 g/day, most of which (at least 90%) being LA, and which was responsible for about 7% 
of daily energy intake. LA is converted, through a series of steps, to γ-linolenic acid, dihomo-γ-
linolenic acid and to arachidonic acid (ARA) [13]. The latter is the major precursor of eicosanoids 
converted by cyclooxygenase-1 (COX-1) to prostaglandins/thromboxanes. Concentrations of ARA-
derived eicosanoids are elevated in people with inflammatory conditions [14]. The pathway to ARA 
synthesis from LA is generally saturated in the presence of a high intake of LA in humans (likely to 
be around 10 g/d). Thus, raising LA intake will have no further effect on the promotion of ARA 
synthesis, and therefore will not alter ARA levels in circulating mononuclear cells (MCs) and 
inflammatory markers in individuals on a normal diet [15]. 
The major potential effect of LA itself on inflammation is via its metabolism to lipoxygenase 
(LOX) derivatives such as the hydroxydecadienoic acids (HODEs) and further, to oxo-HODEs and 
epoxy-HODEs [20]. These compounds play a role in inflammation and have been detected in colonic 
mucosal biopsies of patients with ulcerative colitis without being significantly associated with the 
degree of inflammation [16]. Dietary LA intake was evaluated in a cross-sectional study in 405 
healthy men and 454 healthy women and found not to be significantly associated with inflammatory 
markers, such as CRP, IL-6, soluble (s) tumor necrosis factor receptor (TNF-R) and sTNF-R2 [17]. An 
epidemiological study in Italy on 1123 subjects (aged 20-98 yr) showed that those with the lowest 
intake of LA had the highest pro-inflammatory IL-6 and CRP [18]. However, when multivariable 
models were used, omega-6 fatty acids were positively associated with IL-1 receptor antagonist (IL-
1RA) and negatively with IL-10 and transforming growth factor beta (TGFβ), two powerful 
antiinflammatory cytokines. Similar conclusions were reached in 67 obese individuals randomly 
assigned to receive either 10-week isocaloric diet high in vegetable n-6 PUFA or SFA mainly from 
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butter. n-6 PUFAs did not cause any signs of inflammation, but instead led to a reduction of IL-1RA 
and TNF-R2. No changes in CRP, IL-1β , IL-6 or IL-10 were found [19]. 
This and other studies have led to the conclusion that, despite a long-held belief to the contrary, 
available evidence does not support that high dietary intake or high plasma concentrations of LA 
raise tissue ARA or alter concentrations of inflammatory markers in humans. Since LA can limit the 
synthesis of eicosapentaenoic acid (EPA) from α-linolenic acid in humans, there is the possibility 
that low LA in the background diet might limit endogenous EPA synthesis, potentially creating a 
more inflammatory environment [20]. 
The lack of a significant anti-inflammatory effect of LA or omega-6 fatty acids in general does 
not rule out a beneficial action in CV prevention. Such an effect is supported by the recent 
Consortium Evaluation of 30 prospective observational studies from 13 countries (follow up ranging 
between 2.5 to 31.9 years) [21], in which high levels of LA were significantly associated with a lower 
risk of total CVD (hazard ratio [22]: 0.93; 95% CI, 0.88-0.99), CV mortality (HR: 0.78; 95% CI 0.70-
0.85) and ischemic stroke (HR: 0.88; 95% CI 0.79-0.98). ARA levels were not associated with a high 
incidence of CV outcomes. However, another recent meta-analysis has not confirmed these results, 
and Mendelian Randmization results suggested that individuals with genetically higher serum 
adrenic acid (AA; 22:4,n-6 - naturally occurring PUFA formed through a 2-carbon chain elongation 
of ARA) levels had a greater risk of coronary heart disease (CHD) events (inverse variance weighting 
[IVW]=Beta: 0.526, p=0.007), myocardial infarction (MI) (IVW=Beta: 0.606, p=0.017) and stroke 
(IVW=Beta: 1.694, p=0.009) [26]. 
Special members of the omega-6 fatty acid series are the conjugated linoleic acids (CLA), a 
group of positional and geometric isomers of linoleic acid (LA, 18:2 n-6). Present in meat and dairy 
products and synthesized endogenously, CLA can bind peroxisome proliferator-activated receptor 
alfa (PPARα), a nuclear receptor regulating  fatty acid catabolism and inflammatory responses [23]. 
Of special interest for this widely consumed nutraceutical is its activity on neuroinflammation, 
potentially protective against Alzheimer disease [24]. However, the use of CLA, as well as all other 
omega-6 fatty acids, by patients, as a general anti-inflammatory awaits more convincing 
demonstrations (Table 3). 
 
Omega-3 fatty acids  
Dietary intake of omega-3 fatty acids is essential for health since these PUFAs cannot be 
endogenously synthesized to a significant extent [29]. Omega-3 PUFAs are regarded as anti-
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inflammatory, exerting their activity via multiple mechanisms [25]. The basic mechanism is the 
incorporation of EPA and docosahexaenoic acid (DHA) into cell membranes at the expense of ARA, 
resulting in inhibited ARA metabolism and the consequent decreased expression of the COX gene 
and, as a final consequence, reduction of ARA derived eicosanoids. Finally, partial inhibition of a 
number of aspects of inflammation, including leukocyte chemotaxis, adhesion molecule expression 
and leukocyte-endothelial adhesive interactions, production of inflammatory cytokines, and T-
helper 1 lymphocyte reactivity have to be considered [26]. 
More recently, a major advancement in the field of PUFA and inflammation has been the 
discovery of the so-called pro-resolving lipid mediators produced from EPA and DHA. These 
mediators include resolvins from EPA (E-series) and DHA (D-series) and protectin and maresin from 
DHA. Their synthesis involves the COX and lipopxygenase (LOX) pathways operating in a transcellular 
manner. Early steps can occur in one cell type and the latter in another [27]. Resolvins and maresins 
can be found in humans after EPA or DHA intake [28] and have shown anti-inflammatory benefits in 
vitro and in animal models of inflammation [29]. By these mechanisms, omega-3 PUFA and 
especially DHA decrease the expression of adhesion molecules such as intercellular adhesion 
molecule-1 (ICAM-1) on the surface of endothelial and cells and monocyte cultures as well as of the 
scavenger receptor A in rats fed a high-fat fish oil diet [30] (Figure 1). Interesingly, these properties 
have been now used in the studies on the potential critical role of omega-3 acids in coronavirus  
disease 2019 (COVID-19) [35].  
The inhibitory activity on the nuclear factor (NF)-κB is probably exerted by reduced 
translocation of the NF-κ dimer to the nucleus, where it binds to response elements, thus 
upregulating inflammatory gene expression. Exposure of macrophages to DHA lowers the ability of 
toll-like receptor-4 (TLR4) agonists to recruit co-stimulatory molecules, MHC class II, and to 
stimulate cytokine production [31]. 
In view of the relatively simple methods for measuring circulating pro-inflammatory cytokines, 
a randomized controlled trial (RCT) in ageing adults with chronic venous leg ulcers given EPA+DHA 
therapy (2.5 g/d) reported reduced IL-6, IL-1β  and TNF-α after 4 and 8 weeks of treatment [32]. An 
ongoing trial will evaluate in 248 eligible adults (≥55 years) with chronic venous leg ulcers the 
effectiveness of EPA (1.87 g/day) + DHA (1.0 g/day) to target and to reduce excessive systemic and 
local activation of polymorphonuclear leukocytes [33]. 
A direct evaluation of the two fatty acids was carried out by Allaire et al. [34], testing in a 
double-blind fashion supplementation of EPA and DHA (both 2.7 g/d) vs corn oil (control group) for 
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a period of 10 weeks. Compared with EPA, DHA appeared to lead to a larger reduction of IL-18 (-7.0 
vs -0.5%), hsCRP (-7.9% vs -1.8%) and TNF-α (-14.8% vs -7.6%) and to increased adiponectin (+3.1% 
vs -1.2%) vs EPA; effects on IL-6 (-12.0% vs -13.4%) were similar. Interestingly DHA led to a more 
pronounced reduction of triglycerides (-13.3% vs -11.9%) and a larger increase in HDL-C (+7.6% vs -
0.7%) and LDL-C (+6.9% vs +2.2%) vs EPA. Different conclusions were reached by Pisaniello et al. 
reporting that supplementation with EPA, more than DHA, ameliorates acute and chronic vascular 
inflammation. EPA (4 g/day) reduced the expression of C-C motif chemokine ligand 2 (CCL2) by 25% 
and vascular inflammation compared to placebo [35]. Additionally, available reports suggest that 
purified EPA may have effect on red cell distribution width (RDW) and its association with chronic 
inflammation and red blood cells deformability [41,42]. 
These findings have become of great interest after the positive outcome of the Reduction of 
Cardiovascular Events with Icosapent Ethyl - Intervention Trial (REDUCE-IT) using a high dose of 
highly purified EPA (icosapent ethyl, IPE, 4g/day) given to secondary prevention CV patients or 
patients with diabetes and multiple risk factors on statin therapy, but with moderately elevated 
triglycerides (135-499 mg/dL) [43]. This intervention resulting in a primary CV endpoint reduction 
of 25% in treated patients [36]. At five years, these patients had a median TG reduction of -20% with 
a non-significant change in HDL-C. The lipid findings, particularly those pertaining to TG, were 
interpreted as not fully explaining the observed large CV benefit. Interestingly, however, at the last 
visit, hsCRP levels were reduced by rougly 37%, thus probably adding to the CV benefit of EPA intake 
[43]. In this context, it is worth recalling that prominent in this area were the previous results of the 
JELIS (Japan eicosapentaenoic acid (EPA) Lipid Intervention Study) trial, in which 
hypercholesterolemic patients were randomized to 1.8 g/day high-purity EPA vs placebo. The 
relative risk of major coronary events was reduced by 19% over a 4.6-year-mean follow-up [37]. The 
cardioprotective effects were also observed in a recent meta-analysis of 13 studies with 127,447 
individuals, in which the authors showed a significant reduction of the CHD death risk (risk ratio [38] 
0.91, 95%CI 0.85–0.97), major vascular event (0.95, 95%CI 0.93–0.98), non-fatal MI (0.89, 95%CI 
0.83–0.95), and all-cause mortality (0.95, 95%CI 0.92–0.99) with omega-3 intervention [45].   
More recently, the REDUCE-IT findings were not confirmed in another secondary prevention 
trial, this time in patients given a pre-formulated mixture of EPA and DHA (4 g/day). The STRENGTH 
study did not result in CV benefits (similarly to all previous studies and trials with the mixture of 
omega-3 acids) and was terminated early due to a lack of evident protective activity. hsCRP was 
reduced by -20.0% in the group receiving omega-3 carboxylic acid formulation vs −6.3% in the 
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placebo arm [39]. Moreover, the EVOLVE (The EpanoVa fOr Lowering Very high triglyceridEs) study 
did not show significant reduction in the levels of hsCRP from baseline in patients with 
hypetriglyceridemia upon administration of different daily doses of omega-3 fatty acid (2 g, 3 g or 4 
g) vs olive oil (placebo) [40].  
Debate on the differences between the two studies, besides the different composition of the 
two formulations, has also taken into account differences between the two placebos (mineral oil in 
REDUCE-IT and corn oil in STRENGTH) [41], and while some have argued whether mineral oil’s effect 
on increasing hsCRP may have exaggerated the effects seen in REDUCE-IT, an analysis showed the 
reduction in REDUCE-IT was similar both in those whose hsCRP increased or not [48]. Neutral effects 
from omega-3 were also reported in earlier studies [42, 43]. The ASCEND (A Study of Cardiovascular 
Events in Diabetes) trial evaluated the efficacy of EPA and DHA in doses recommended by the 
Nutrition Committee of the American Heart Association, i.e., 460 mg and 380 mg, respectively. After 
a mean follow-up of 7.4 years, there was no significant difference between the treatment and 
placebo groups with respect to the occurrence of a composite MI, stroke, transient ischemic attack, 
or vascular death: HR of 0.97 (95%CI 0.87-1.08; p=0.55) [44]. The superiority vs placebo of similar 
doses of EPA/DHA to reduce MI, stroke, or CV death in primary prevention was the objective of the 
VITAL (Vitamin D and Omega-3 Trial) study [45]. Over a median of 5.3 years of follow-up, the HR was 
0.92 (95%CI, 0.80-1.06; p=0.24) [52]. 
 
Nutraceuticals as non-absorbable agents 
In addition to  PUFAs, the evaluation of nutraceuticals extends from dietary components of 
common foods to non-absorbable and absorbable agents, with recognized anti-inflammatory 
activities, and to specific functional foods. 
Among non-absorbable nutraceuticals, sterols/stanols, soluble fibers (β-glucan, psyllium, 
glucomannan and non-fiber chitosan) might demonstrate antiinflammatory properties, among 
others, due to their clear lipid-lowering activity [13]. The beneficial impact of dietary fiber on 
circulating CRP levels has been also observed in a comprehensive meta-analysis of RCTs [53], 
however these results are still limited and inconclusive. An anti-inflammatory action of non-
absorbable nutraceuticals has been reported in obese patients with osteoarthritis [46], but 
observational studies have not been still supported by controlled investigations.  
Plant stanol esters are widely available as rapeseed oil-based spreads, and other phytosterols 
are commonly-used nutraceuticals for moderate cholesterol reduction (-10-15%) [47, 48]; however, 
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potentially rare harmful effects have been observed. These molecules, which affect cholesterol 
absorption, may lead to hypercholesterolemia and elevated CV risk in some rare genetic 
abnormalities of the ABCG5/ABCG8 transporters [49]. 
Recently an inflammation-like phenomenon appeared to be reduced by plant stanol 
supplementation (2-3 g/d). Patients with modest cholesterol elevations experienced a clear 
reduction of LDL aggregation after treatment with stanol esters [50]. The decrease in aggregation 
was more extensive in participants with a body mass index (BMI) <25 kg/m2. Decreased aggregation 
was associated with a reduced proportion of LDL sphingomyelines and increased LDL triglycerides. 
Since LDL particles are more susceptible to aggregation in individuals with established CVD, an 
aggregation prone-LDL may predict future ASCVD independent of conventional risk factors [51].  
Further studies are still necessary to confirm their direct and indirect effects on different 
inflammatory parameters.  
 
Nutraceuticals as absorbable agents 
Among absorbable nutraceuticals, probiotics can reduce cholesterol by modifying gut flora, in 
particular, by providing enzymes catalyzing the transformation of cholesterol into cholest-4-en-one, 
an intermediate in the conversion to coprostenol or coprostanol, directly excreted into faeces. 
Probiotics such as Lactobacillus acidophilus, Bifidobacterium bifidum or bulgaricus can reduce the 
enterohepatic circulation of cholesterol by activation of bile-salt hydrolase [52], consequently 
increasing excretion [53]. Probiotics may also help to reduce the lecithin/carnitine derived 
trimethylamine-N-oxide (TMAO) and the consequent inflammatory changes [54]. The anti-
inflammatory activity of probiotics appears to be linked to immune regulation. Activated regulatory 
T (Treg) cells are reduced by L.reuteri in pregnant women in the second half of pregnancy with 
treatment independent changes in lymphocytes and monocytes and in subpopulations of T-helper 
cells [55]. Interest in the clinical use of L.reuteri has grown after the positive clinical studies in 
inflammatory bowel [56].  
Among absorbable nutraceuticals, also flavonoids are enjoying a growing interest. These 
compounds are widely consumed components of food. Subclasses of flavonoids, including catechins 
and flavanols, present in cocoa and green tea, have received the most interest [57]. They exert 
powerful antioxidant properties, together with the ability to inhibit the secretion of pro-
inflammatory cytokines and chemokines from activated endothelial cells. The anti-inflammatory 
effect of flavanols has been demonstrated in a few studies by the supplementation of FRLFE 
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(flavanol-rich lychee fruit extract) [58]. In healthy individuals, during submaximal and maximal 
exercise workloads, FRLFE supplementation (100 mg/d for four weeks and two months) reduced the 
concentrations of the pro-inflammatory cytokines IL-1β  and IL-6 as well as cortisol. The 
concentration of TGF-β  was increased. Supplementation with FRLFE for 30 days in regular exercising 
males at maximal workloads also significantly increased time to exhaustion [59]. 
The anti-inflammatory activity of flavanols may work in harmony with potential vascular 
protective effects, in particular those exerted by cocoa flavanols [68]. This recognition has led to the 
indication of black flavanol-rich chocolate in blood pressure control, which also has the potential to 
improve cognitive performance in the elderly [60, 61]. A large clinical study on the preventive 
activity of a flavanol-rich cocoa-equivalent in hypertensive patients is ongoing and will also evaluate 
inflammatory markers (COcoa Supplement and Multivitamin Outcomes Study (COSMOS) [62]. This 
has led to the identification of possible additional indications, such as peripheral artery disease 
(PAD). A six-month double-blind, RCT in these patients evaluated cocoa (15 g cocoa and 75 mg 
epicatechin daily) vs placebo. An improvement in the 6-min walk distance at the 6-month follow up, 
by 42.6 meters 2.5 hours after the final study beverage and 18. meters at 24 hours, compared to 
placebo, was reported [63]. Data from muscle biopsies in treated patients were clearly indicative of 
an improvement in microvascular parameters, with significantly raised mitochondrial and capillary 
densities, possibly dependent on higher VEGF-A (Vascular Endothelial Growth Factor-A) levels [74]. 
The antioxidant activity of flavanols does not appear to be related to changes in nitrotyrosine and 
4-HNE (hydroxynonenal) [64]. An additional anti-inflammatory activity relates to the reduction of 
the pro-inflammatory cytokine IL1-β  [65]. Large studies investigating the flavanol content and 
inflammatory consequences of a Mediterranean diet, such as the Prevención con Dieta 
Mediterránea (PREDIMED) study, detected a reduction of inflammatory markers together with a 
clear CV benefit [66]. 
Curcumin is a dietary polyphenol derived from the root of Curcuma longa, commonly known as 
turmeric. Curcuma contains approximately 5% curcuminoids by weight. Curcumin has traditionally 
been used for chemopreventive and antioxidant properties. Potential health benefit in metabolic 
syndrome has been reported, resulting in a significant decrement in serum concentrations of TNF-
α, IL-6, TGF-β  and MCP-1 [67]. Whilst curcumin exerts a modest lipid-lowering effect, potentiating 
the effects of phytosterols [68], it also exerts definite antioxidant and anti-inflammatory effects [69]. 
Potential mechanisms underlying this effect are thought to relate to inhibition of NF-κB  and TLR-4 
signalling and activation of the PPARγ  pathway [70].  More recently, potential up-regulation of mir-
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126, leading to inhibition of PI3K/AKT and JAK2/STAT5 signalling pathways, has been reported [71]. 
These anti-inflammatory actions have been exploited to ameliorate symptoms and reduce the 
burden of clinical inflammation in several diseases (e.g., inflammatory bowel disease, psoriasis, 
etc.); these properties of curcumin are also currently under investigation in a variety of other clinical 
conditions in the ongoing studies [70]. A significant reduction of circulating IL-6 (standardized mean 
difference [SMD] -2.08) and CRP levels (SMD -0.65) was reported in a recent meta-analysis of 15 
RCTs [84]. A previous meta-analysis of 6 trials testing the impact of curcuminoids on circulating CRP 
revealed that the overall significant anti-inflammatory effect of curcuminoids was dependent on the 
bioavailability of the different preparations [85]. 
The bioavailability of curcumin is low following oral use, and a number of reports have 
investigated if the use of novel formulations and absorption ehancers could boostthe 
pharmacological effects [86]. Recently, a phospholipid-curcumin complex was found to be better 
absorbed and to provide higher benefit at a 250 mg/day dosage (equivalent to 50 mg of curcumin) 
in conditions such as non-alcoholic fatty liver disease (NAFLD). In a double-blind study, positive 
changes in the liver proteome were reported after 8 weeks of administration [72]. Moreover, 
several studies have shown that co-administration of curcumin with the alkaloid piperine might be 
effective in enhancing the bioavailability of the former; the anti-inflammatory effects of this 
combination has been reported in RCTs [87]. A prodrug hypothesis has been very recently proposed 
in order the explain the anti-inflammatory activity of curcumin in the absence of adequate 
bioavailability [73]. Curcumin can undergo extensive glucuronidation in plasma and curcumin 
glucuronide may act as an inflammation responsive natural prodrug, being later converted back to 
curcumin in inflamed target tissues. By this mechanism, curcumin would act as a direct anti-
inflammatory and potentially anti-tumoral agent [88]. 
Bergamot is the common name of the fruit Citrus bergami, Risso. It differs from other Citrus 
fruits in composition and richness in flavonoids. Bergamot essential oil (BEO) and bergamot juice 
(BJ) contain up to 93-96% volatile compounds such as monoterpenes (mainly limonene) and 4-7% 
nonvolatile compounds, such as pigments, waxes, coumarins, and psoralens [74]. Some Bergamot 
fractions were found to have statin-like actions, inhibiting HMG-CoA reductase [75], indicating that 
bergamot (generally at the dose of 1000 mg/day) can lower total and LDL-cholesterol in patients, in 
addition to reducing oxidized LDL [76]. Its lipid-lowering potential and safety has led to the 
recommendations of bergamot in statin intolerant patients (IIa B) in the ILEP Position Paper  in 2018 
[92]. 
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The anti-inflammatory activity of bergamot might be associated with a reduction in pro-
inflammatory cytokines [77], the mechanism occurring via SIRT1-mediated NF-κB inhibition in THP1 
monocytes. An in vitro protective effects of bergamot peel extract on endothelial cells exposed to 
tumour TNF-α  was found to be associated with reduced intracellular levels of malondialdehyde/4-
hydroxynonenal and raised oxidized glutathione and superoxide dismutase activities [78]. The anti-
inflammatory activity of bergamot could be of potential clinical interest, as reported in experimental 
periodontal disease, where bergamot reduced tissue injury and several markers of gingival 
inflammation, including nuclear NF-κB translocation, cytokine expression, myeloperoxidase activity 
and adhesion molecules such as ICAM and P-selectin [79]. In inflammatory bowel disease, 
administration of bergamot was found to reduce the release of pro-inflammatory cytokines and 
decrease apoptosis, with an increase of antiapoptotic BCL-2 in a model of ischemia-reperfusion 
injury [80]. Bergamot appears not to exert any serious adverse effects, and interest in the potential 
use in dental and cardiological patients remains active, however more clinical data on the potential 
anti-inflammatory activities of bargamot is still necessary.  
Garlic (Allium sativum) has been traditionally believed to be endowed with numerous beneficial 
properties, including lipid-lowering and antihypertensive actions. While many of these actions have 
not been definitively confirmed, a number of studies have reported potential activity of garlic in 
allergic conditions and dermatitis. Garlic contains the non-protein aminoacid allicin, characterized 
by the content of hydrogen sulphide (H2S), a potential nitric oxide (NO) agonist. Recently a large 
meta-analysis of 16 RCTs [81] reported that garlic doses ranging from 1200 to 3600 mg/d for a 
duration of 2 to 52 weeks significantly reduced CRP (-0.61 mg/L), IL-6 (0.73 ng/L) and TNF-α (-0.26 
ng/L), with no activity on adiponectin and leptin, thus indicating that a potential mechanism on 
inflammatory and CVD disorders needs still to be evaluated. A further activity of potential clinical 
interest is the antagonism of the pro-inflammatory adipocytokines resistin and TNF-α by garlic 
supplementation leading to reduced severity of pain in overweight and obese women with knee 
osteoarthritis in a RCT [82]. 
Berberine is a quinolone alkaloid found in various medicinal plants, including Coptis chinensis 
and Berberis aristata. In addition to the many traditional activities described in the old literature, 
recent years have provided evidence of significant stimulatory activity on LDL receptors (with the 
class IA in the ILEP recommendations) [83]. This experimental observation was later supported by 
numerous studies in hyperlipidemia and diabetes. Berberine also appears to have a unique 
mechanism, i.e., that of reducing peripheral branched-chain amino acids (BCAA); by this mechanism, 
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it can improve insulin resistance in experimental models and in humans [84]. This mechanism may 
be potentially associated with direct anti-inflammatory effects described in animal models such as 
apo E-/- mice [85], thus suggesting the potential to reduce atheroma plaque size, vulnerability, 
inflammation and oxidative stress. Unfortunately, the bioavailability of berberine is poor, but clinical 
use in European countries in combination with red yeast rice has found wide support [102]. An 
unexpected activity of berberine was recently observed in a model of experimental NAFLD, i.e. the 
reduction of the inflammatory response by way of SIRT3-mediated  long-chain acyl CoA 
dehydrogenase (LCAD) deacetylation [86]. In NAFLD induced by a high-fat diet in mice, pro-
inflammatory cytokines (CCL2, TNF-α) are increased, as is the infiltration of inflammatory cells 
(CCR2), hepatic mRNA and levels of angiopoietin-like 2 (Angptl2), NF-κB and forkhead box protein 
O1 (Foxo1). Following barberine treatment, liver tissue pathology, biochemical data, and the 
Angptl2 pathway-related genes are significantly ameliorated [87]. 
Despite large lipid-lowering potential and available experimental studies with barberine on its 
antiinflammatory properties, there are still limited clinical data on the potential role of barberine 
on the inflammatory parameters. The meta-analysis of 5 RCTs showed that serum levels of CRP were 
significantly decreased after barberine supplementation (-0.64 mg/L). Based on these results, the 
authors concluded that especially CVD and diabetic patients are two important groups, which might 
benefit from barberine supplementation, however further well-designed, longer studies with larger 
samples are needed to ascertain the effects of barberine on chronic inflammation [104]. 
Red yeast rice (RYR) is a prodrug derived from a contaminant of rice containing the yeast 
Monascus purpureus, from which statins were originally extracted. RYR contains monacolin K, 
chemically identical to lovastatin, in concentrations around 2%. A number of studies have evaluated 
RYR by itself or as purified derivatives enriched with monacolin K. The cholesterol-lowering activity 
has been well described and is comparable with that of lovastatin [105]. In last several years, there 
have been a large debdate on the RYR safety, however recent raports, incluing postmarketing 
nutrivigilance reports (based on data from 2.3 million consumers), clearly confirmed its large safety, 
even in patients with statin intolerance [88].  
A raw extract of RYR, xuezhikang, given in doses of 1200 to 1400 mg/day, was associated with 
a 45% reduction in CHD events over 4.5 years, as well as significant reductions in CV and total 
mortality in a large controlled secondary prevention study [89]. In coronary patients, xuezhikang 
(1200 mg/day) given for six weeks also led to a 50% reduction in fasting hsCRP reduction compared 
to placebo. This decrement was correlated to an improved preprandial and postprandial flow-
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mediated dilatation (FMD), an index of endothelial function [90]. Similar conclusions were reached 
when patients with stable angina were considered. After 14 days, xuezhikang (1200 mg/day or 2400 
mg/day) reduced by roughly 28% the levels of hsCRP from baseline, an effect irrespective of the 
dose [91]. 
A number of specifically targeted studies of RYR in inflammation have been published recently, 
potentially indicating an improvement of endothelial dysfunction. Monacolin K promotes and 
stabilizes the expression of endothelial nitric oxide synthase (eNOS) and uncouples 
tetrahydrobiopterin (BH4) [92]. The anti-inflammatory mechanism of RYR is quite similar to that of 
statins, i.e., suppression of NF-kB binding to cells and inhibition of the IP3K/AKT/nGOR pathway and 
histone deacetylase 1 [93]. This may lead to the inhibition of mitogen-activated protein kinases 
(MAPKs) participating in inflammation through various subfamilies (JNK, ERK 1/2 and p38 kinase). 
Inflammation occurring atherosclerosis induced by a high-fat diet is suppressed by RYR via the 
blocking of MAPK signalling pathways [94]. RYR may thus reduce the expression of pro-inflammatory 
mediators through the PK signalling pathway and inhibited NO release, thereby ameliorating 
inflammation-linked diseases mediated by excessive and/or prolonged activation of immune cells 
[95] (Figure 2). In in vitro conditions RYR reduced TNFα by down-regulating the NF-κB activatity and 
reducing the intracellular production of reactive oxygen species (ROS) in aortic smooth muscle cells 
(SMC) [96], thus supporting the conclusion that the anti-inflammatory effect may be similar to that 
of statins and may be of potential benefit in CV prevention [117,118]. 
 
Dietary plant proteins  
Dietary plant proteins have been associated, in a number of recent epidemiological studies, 
with a significant protective effect against CV disease  [97]. Dietary studies with the use of specific 
proteins have largely focused on soy and lupin. The use of soy proteins for the treatment of 
hypercholesterolemia dates back several decades  [98, 99]. In recent years, this type of dietary 
approach to severe hypercholesterolemia has been utilized to a far lesser extent, mainly because of 
the commercial availability of statins, which have dramatic activity on upegulating the LDL receptor 
on heatocytes. 
Among the consequences of frequent use of this diet amongst normocholesterolemic or 
moderately hypercholesterolemic individuals, a number of erroneous conclusions were drawn. The 
first is that soy proteins do not possess a hypocholesterolemic activity: this was contradicted by the 
observation that soy proteins and components such as the 7S globulin markedly activate LDL-R 
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expression in animals [100] and in patients with familial hypercholesterolemia [101]. The second 
erroneous conclusion is that other components such as phytoestrogens present to a variable extent 
in commercial soy preparations but absent, e.g., in lupin, may be responsible. Phytoestrogens do 
not exert any significant hypocholesterolemic activity [102, 103].  
The anti-inflammatory activity of soy and lupin proteins is again likely dependent in both cases 
on the protein component [126], but the presence in soy of other non-protein moieties may perhaps 
contribute to some extent to the anti-inflammatory activity without having any effect on 
cholesterol. 
Soy proteins. Dietary soy proteins are available as a mixture of proteins and peptides, with 
additional components, including fibers and phytoestrogens. Phytoestrogens may be of some 
benefit in the relief of symptoms in post-menopausal women. However, the results of the studies 
are not conclusive [104]. Some clinical benefit on inflammatory markers was reported in women 
with metabolic syndrome [105]. In this last study, consumption of soy-nut was compared with that 
of soy proteins and red meat. Soy-nut exerted a clearly better anti-inflammatory activity compared 
with soy proteins and red meat. In particular, IL-18 was reduced by -9.2% by soy-nuts compared 
with meat, but soy proteins had no activity. With respect to CRP, the difference from the red meat 
diet was significant (-8.9%) on the soy-nut diet and -1.6% on the soy protein diet [128]. While in this 
study, phytoestrogen intake may have played an important role, more recent studies have been 
focused on the protein components themselves. Detailed investigations have described bioactive 
anti-inflammatory peptides (BAPs) released from dietary proteins by enzymatic digestion in the 
intestine. BAPs, at concentrations of 200-1,000 µM, inhibit inflammation by the MAPK or NFK-β  
pathways [106]. This type of antagonism to inflammatory cytokine expression can also be exerted 
by soybean derived dipeptides and tripeptides [107]. 
Contradictory and inconclusive findings have been reported in two meta-analyses evaluating 
the effect of soy supplementation on inflammatory biomarkers. The first meta-analysis comprising 
36 studies published before December 2016 showed a non-significant 0.19 mg/dL reduction in the 
levels of hsCRP upon consumption of soy products [131]. Subgroup analysis highlighted that this 
effect was mainly driven by natural soy products in comparison with other sources of isoflavones, 
being the levels of the latter significantly correlated with serum hsCRP [108]. A second meta-analysis 
comprising 51 RCT reported that supplementation with soy products led to a significant reduction 
of hsCRP (-0.27 mg/L; 95%CI -0.51, -0.02) but not IL-6 and TNF-α. However, the effect became 
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significant when studies with a long-term design (≥12 weeks) and low dose isoflavone (<100 
mg/day) were chosen [109].  
The soy diet has been shown to result in remarkably reduced colon inflammation in pigs with 
dextran-sulphate induced colitis [107]. Furthermore, clear evidence has been now provided that 
these small molecules can be transported from the intestine into the bloodstream of humans or 
animals by the peptide transporter (hPepT1) system [110], thus indicating the potential for soybean 
proteins to affect generalized inflammatory diseases such as atherosclerosis and hypertension 
[111]. The potential of soy protein diets to exert lipid-lowering effects in hypercholesterolemic 
individuals, and to affect inflammation, may lead to advances in the prevention of ASCVD and the 
development of protein or peptide fractions with improved activity. 
Lupin proteins. Proteins from white lupin seed are essentially phytoestrogen free and exert a 
similar activity to soy on cholesterolemia in rodents [112, 113]. This occurs via stimulation of the 
activity of LDL-R. Proteins from lupin have been investigated to a lesser extent than soy in the clinical 
treatment of hypercholesterolemia, but results have been encouraging [114].  Some lupin proteins  
have been demonstrated to have anti-inflammatory activity. The most active is γ-conglutin, a small 
protein that is associated with improvements in insulin resistance in vitro [115]. This protein has 
been extensively studied for a potential hypoglycemic activity [116], but in addition, it has been 
shown to have a potential role in the regulation of blood pressure by inhibiting the activity of 
angiotensin converting enzyme (ACE) [117]. Peptides with inhibitory activity against ACE can be 
obtained by direct enzymatic hydrolysis of lupin [118]. These peptides appear to provide a range of 
potential activities besides those on lipids and blood pressure. Specifically, the anti-inflammatory 
activity [119], in addition to the lipid-lowering mechanism, may offer an important tool for CV 
prevention. Lupin peptides were recently investigated for their anti-inflammatory activity on 
RAW264.7 cells (cell line origin: mouse monocyte macrophage) [120]. Among peptides isolated from 
the gastroduodenal digests of extruded lupin, the lupine peptide monomer IQDKEGIPPDQQR was 
the most promising, significantly inhibiting lipoprotein polysaccharide (LPS) induced activation of 
TNF-α, IL-6, IL-1 β  and MCP-1 production by 40-50% at a concentration of 10 µM [143]. Lupin 
proteins appears not to exert any serious adverse effects, however the clinical data on their 






Increased recognition of the problem of the residual CV risk in optimally drug-treated patients 
has led to a more intensive evaluation of non-drug approaches, in particular nutraceuticals. Despite 
we have had mostly data on their influence on selected inflammatory parameters, and we would 
like again to strongly emphasize that nutraceuticals cannot replace pharmaceutical therapy, they 
might be of high value, especially having still limited therapeutic antiinflammatory options, 
especially when optimal therapy is highly expected in the time of Covid-19 pandemic.  
Indeed, as has been reviewed elsewhere [9], not all recent drug-based anti-inflammatory 
interventions aimed at reducing CV burden have been successful. While in the CANTOS 
(Canakinumab Antiinflammatory Thrombosis Outcome Study) trial, the use of canakinumab (anti-
IL1β) led to a 15% reduction in CV events, and a similar outcome occurred in the COLCOT (Colchicine 
Cardiovascular Outcomes Trial) study with colchicine (-13%), a neutral effect was described in the 
CIRT (Cardiovascular Inflammation Reduction Trial) study with methotrexate (HR 1.01; 95% CI 0.82–
1.25). Furthermore, in an Australian trial enrolling patients with acute coronary syndromes, the 
addition of colchicine to standard medical therapy did not significantly affect CV outcomes at 12 
months and was associated with a higher rate of mortality [121]. Irrespectively of the above 
mentioned, none of these drugs is available on the market to treat inflammatory-linked CVD residual 
risk, and it seems only colchicine might be soon useful, but also in the patients with strictly described 
indications [145,146].  
This detailed overview of nutraceuticals addresses their effect on inflammatory parameters   
and offers a promising insight into the role of natural molecules or functional foods with the 
potential to reduce the inflammatory burden associated with CV diseases. These are the first 
recommendations that provide a clear message on the nutraceuticals with the potential to reduce 
inflammation. These generally well-tolerated products are increasingly used in the community and 
may provide, due to their multiple properties (lipid-lowering, anti-inflammatory, anti-oxidant, 
hypoglycemic, etc.), some benefits in conditions of raised CV risk, which is not fully addressed by 
currently available pharmacological treatments. 
Besides the effectiveness of selected nutraceuticals to reduce inflammatory parameters levels,  
equally important, despite still insufficient data, is that this therapy seems to be safe and well 
tolerated. However, further studies in individuals with inflammatory conditions, especially in those 
with residual CVD risk due to inflammation (with suitably large group of patients and longer follow-
up), are still necessary to confirm the effectiveness and safety of nutraceuticals (with a specific 
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dosage), to prove that they maintain their efficacy in the long-term, as well as to answer the 
question of whether this therapy might have a positive effect on CV outcomes. 
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Class I Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, 
effective. 
Is recommended/ is 
indicated 
Class II Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given 
treatment or procedure. 
 
  Class IIa Weight of evidence/opinion is in favour of usefulness/efficacy. Should be considered 
  Class IIb Usefulness/efficacy is less well established by evidence/opinion. May be considered 
Class III Evidence or general agreement that the given treatment or procedure is not useful/effective, and 
in some cases may be harmful. 
Is not recommended 
 
 
Table 2. Level of evidence. 
 
Level of evidence Definition 
A Data derived from multiple randomized clinical trials or their meta-analysis 
B Data derived from single randomized clinical trial or large non-randomized studies 






Table III.  ILEP recommendations on the effect of nutraceuticals on inflammatory parameters.  
 
 Class Level   
Omega- 6 fatty acids 
IIb B 
No inhibition of CRP, IL-6, soluble (s)TNF-R and 
sTNF-R2 
[17] 
 Positively associated with IL-1RA and negatively 
with IL-10 and TGF-β, anti-inflammatory cytokines 
[18] 
 Reduction of IL-1RA and TNF-R2. No changes in CRP, 
IL-1β , IL-6 and IL-10 
[19] 
 
Omega- 3 fatty acids1 
I A 
EPA+DHA therapy (2.5 g/d) reduced IL-6, IL-1β  and 
TNF-alfa 
[32] 
 Compared with EPA, DHA led to a larger reduction 
of IL-18 (-7.0% vs -0.5%), hs-CRP (-7.9% vs -1.8%) 
and TNF-alfa 14.8% vs -7.6%). Reductions of IL-6 
were similar (-12.0% vs -13.4%) 
[34] 
 Purified EPA may have effect on red cell distribution 
width (RDW) and its association with chronic 
inflammation and red blood cells deformability 
[41,42] 
 EVOLVE study (omega-3 free fatty acid 2 g, 3 g or 4 
g/day) no significant changes in hs-CRP from 
baseline (-0.3 mg/L) compared twith placebo (-
0.2mg/L) 
[40] 
 REDUCE-IT study (icosapent ethyl 4 g/die) 
hsCRP: -37.6% (between group difference) 
[36] 
 STRENGTH study (carboxylic acid formulation of 
EPA and DHA) 
hs-CRP: -20.0% in the group receiving omega-3 





Flavonoids IIa B Reduction in IL-1β  and IL-10 [[65] 
     
Curcumin 
IIa B 
A significant decrement in serum concentrations of 
TNF-α, IL-6, TGF-β  and MCP-1 
[67] 
 TNF-α, -4.69 pg/mL [69] 
     
Bergamot 
III C 
In vitro: decrement in intracellular levels of 
malondialdehyde/4-hydroxynonenal 
[78] 
 Preclinical periodontal disease: reduced tissue 
injury and several markers of gingival inflammation 
In inflammatory bowel disease: reduce the release 
of pro-inflammatory cytokines 
[79] 
[80] 
     
Garlic 
IIb B 
Doses ranging from 1200 to 3600 mg/d for a 
duration of 2 to 52 weeks significantly reduced CRP 
(-0.61 mg/L), IL-6 (0.73 ng/L) and TNF-α (-0.26 ng/L) 
[81] 
     
Berberine 
IIb B 
Berberine might attenuate the liver inflammatory 
response in the livers of rats with high-fat diet-
induced NAFLD 
[87] 
In the meta-analysis of 5 RCTs showed that serum 
levels of CRP were significantly decreased after 
barberine supplementation (-0.64 mg/L). 
[104] 
     
RYR2 I A hsCRP: -50% [90]  hsCRP:-28% [91] 
     
Soy 
IIa A 
CRP: soy-nut diet led to a -8.9% compared with red 
meat diet. 




Meta-analysis: a non-significant 0.19 mg/dL 
reduction in the levels of hsCRP upon consumption 
of soy products 
[108] 
Meta-analysis: significant reduction of hsCRP (-0.27 
mg/L; 95%CI -0.51, -0.02) but not IL-6 and TNF-α 
[109] 
     
Lupin 
III C 
In vitro data: IQDKEGIPPDQQR was the most 
promising, significantly inhibiting lipoprotein 
polysaccharide (LPS) induced activation of TNF-α, 
IL-6, IL-1β   and MCP-1 production by 40-50% at a 
concentration of 10 uM. 
[120] 
 
ABBREVIATIONS: hsCRP, high-sensitivity C-reactive protein; IL, interleukin; MCP-1, monocyte chemoattractant protein-1; NAFLD, non-alcoholic fatty l iver disease; TGF-β, 
transforming growth factor; TNF-α, tumor necrosis factor alfa; EVOLVE, Epanova® for Lowering Very High Triglycerides; REDUCE-IT, Reduction of Cardiovascular Events with 
Icosapent Ethyl–Intervention Trial; STRENGHT, Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with 
Hypertriglyceridemia.  
1There are some safety concerns based on the available studies. In the REDUCE-IT trial increased rates in atrial fibrillation (AF) hospitalization and peripheral edema in the IPE vs 
placebo group (5.3% vs 3.9%, p=0.003, and 6.5% vs 5.0%, p=0.002, respectively), were observed; 2There are some safety concerns on RYR- related muscle adverse events. Based 
on the European Food Safety Authority (EFSA) Scientific Opinion from 2018, RYR is not available in all countries (e.g. in Switzerland). A new EU/EFSA Regulation is expected on its 





Figure 1. Role of linoleic acid, docosahexaenoic acid and eicosapentaenoic acid  on inflammatory 
pathways. LA, EPA and DHA are incorporated into the phospholipids of cell membranes at the 
expense of ARA. LA can also be converted, through a series of steps, to γ-linolenic acid, dihomo-γ-
linolenic acid and to arachidonic acid) which is also incorporated into phospholipids of cell 
membranes. Phospholipase A2 catalyzes the release of LA, ARA, EPA and DHA which undergo to 
intracellular metabolism. LA is converted to to proinflammatory mediators oxo-HODEs and epoxy-
HODEs while ARA to PGG2 and PPGH2. LA consumption is negatively associated with IL-1RA, IL-10, 
TGF-β and TNF-R2. EPA and DHA are metabolized  by CYP450, 15-lipoxygenase, 12-lipoxygenase and 
5-lipoxyganase leading to the formation of the pro-resolving lipid mediators, such as resolvins, 
protectin, and maresins. These molecules have been shown to reduce the expression of 
profinflammatory cytokines IL-1β, IL-6, IL-18 and TNF-α. EPA and DHA have been shown to reduce 
hs-CRP plasma levels. The anti-inflammatory effect may affect neutrophil activation, diapedesis and 
ROS synthesis. Reduced expression of adhesion molecules, pro-inflammatory cytokines and ROS 
production may be observed in endothelial cells. Finally, reduce dendritic cells migration and IL-12 
may also be predicted. 
Arachidonic acid (ARA); Docosahexaenoic acid (DHA); Eicosapentaenoic acid (EPA); High-sensitivity 
C-reactive protein (hsCRP); Interleukin (IL); Linoleic acid (LA); Phospholipase A2 (PLA2); 
Prostaglandin G2 (PGG2); Prostaglandin H2 (PGH2); Reactive oxygen species synthesis (ROS); Tumor 
necrosis factor (TNF); Tumor necrosis factor receptor (TNF-R). 
 
Figure 2. Basic mechanism for the anti-inflammatory effect of absorbable agents. Accumulation of 
cholesterol in the atherosclerotic plaque determines the recruitment of macrophages and the 
activation of the inflammasome system. NLRP3 induces caspase-1 activation which, in turn, cleaves 
pro-IL-1β and pro-IL-18 to their active counterparts that induce IL-6. In the liver, IL-6 induces CRP, a 
clinically proven biomarker of inflammatory status and cardiovascular risk. The effect of different 
nutraceuticals on pro-inflammatory and anti-inflammatory mediators are depicted. 
C-reactive protein (CRP); Interleukin (IL); β-Hydroxy β-methylglutaryl-CoA (HMG-CoA); NACHT-, LRR- 













#International Lipid Expert Panel Experts (alphabetically): 
 
Julio Acosta (Cátedra de Cardiología Clínica de la Escuela Médica Razetti de la Universidad Central de 
Venezuela, Caracas, Venezuela); Mutaz Al-Khnifsawi (Al-Qadisiyah University, Faculty of Medicine, 
Department of Internal Medicine, Diwaniya City, Iraq); Fahad Alnouri (Cardiovascular Prevention Unit, Adult 
Cardiology Department. Prince Sultan Cardiac Centre Riyadh, Saudi Arabia), Fahma Amar (Unit of Diabetes 
& Metabolism, Alexandria University, Alexandria, Egypt), Atanas G. Atanasov (Institute of Genetics and 
Animal Biotechnology of the Polish Academy of Sciences, Jastrzebiec, Poland; Department of 
Pharmacognosy, University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Digital Health and 
Patient Safety, Medical University of Vienna, Vienna, Austria), Gani Bajraktari (Institute of Public Health and 
Clinical Medicine, Umeå University, Umeå, Sweden; Clinic of Cardiology, University Clinical Centre of Kosovo, 
Prishtina, Kosovo; Medical Faculty, University of Prishtina, Prishtina, Kosovo), Maciej Banach (Department of 
Hypertension, Medical University of Lodz, Poland; Cardiovascular Research Centre, University of Zielona-
Gora, Zielona-Gora, Poland), Sonu Bhaskar (Department of Neurology & Neurophysiology, Liverpool Hospital 
and South Western Sydney Local Health District, Sydney, NSW, Australia); Bojko Bjelakovic (Clinic of 
Pediatrics, Clinical Center, Nis, Faculty of Medicine, University of Nis, Serbia), Eric Bruckert (Pitié-Salpetrière 
Hospital and Sorbonne University, Cardio metabolic Institute, Paris, France), Richard Ceska (Third 
Department of Medicine - Department of Endocrinology and Metabolism of the First Faculty of Medicine, 
Charles University and General University Hospital, Prague, Czech Republic), Arrigo F.G. Cicero (IRCCS 
Policlinico S.Orsola-Malpighi, University of Bologna, Italy), Xavier Collet (Institute of Metabolic and 
Cardiovascular Diseases, Inserm, Toulouse, France), Magdalena Daccord (FH Europe, Europe), Olivier 
Descamps (Department of Internal Medicine, Centres Hospitaliers Jolimont, Haine Saint-Paul, Belgium; 
Department of Cardiology, Cliniques Universitaires Saint-Luc, Bruxells, Belgium), Dragan Djuric (Institute of 
Medical Physiology "Richard Burian" Faculty of Medicine, University of Belgrade, Belgrade, Serbia), Ronen 
Durst (Cardiology Department, Hadassah Hebrew University Medical Center, Ein Kerem, Jerusalem, Israel), 
Marat V. Ezhov (National Medical Research Center of Cardiology, Moscow, Russia), Zlatko Fras (Preventive 
Cardiology Unit, Department of Vascular Medicine, Division of Medicine, University Medical Centre Ljubljana, 
Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia), Dan Gaita (Institutul de Boli 
Cardiovasculare, Universitatea de Medicina si Farmacie Victor Babes din Timisoara, Romania), Adrian V. 
Hernandez (Health Outcomes, Policy, and Evidence Synthesis (HOPES) Group, University of Connecticut 
School of Pharmacy, Storrs, CT, USA; Vicerrectorado de Investigación, Universidad San Ignacio de Loyola 
(USIL), Lima, Peru), Steven R. Jones (the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, 
Baltimore, MD, USA), Jacek Jozwiak (Department of Family Medicine and Public Health Faculty of Medicine 
University of Opole, Opole, Poland), Nona Kakauridze (Department of Internal Medicine, Faculty of Medicine, 
Tbilisi State Medical University, Tbilisi, Georgia), Amani Kallel (University of Tunis El Manar, Faculty of 
Medicine of Tunis, Tunis, Tunisia); Niki Katsiki (Diabetes Center, Division of Endocrinology and 
Metabolism, First Department of Internal Medicine, AHEPA University Hospital, Aristotle University of 
Thessaloniki, Thessaloniki, Greece), Amit Khera (Department of Cardiology, UT Southwestern Medical Center, 
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Dallas, TX, USA), Karam Kostner (Mater Hospital, University of Queensland, St Lucia, QLD, Australia), 
Raimondas Kubilius (Department of Rehabilitation, Medical Academy, Lithuanian University of Health 
Sciences, Kaunas, Lithuania), Gustavs Latkovskis (Institute of Cardiology and Regenerative Medicine, Faculty 
of Medicine, University of Latvia, Riga, Latvia; Pauls Stradins Clinical University Hospital, Riga, Latvia), G.B. 
John Mancini (Department of Medicine, Division of Cardiology, University of British Columbia, Vancouver, 
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the Royal Free London NHS Foundation Trust, Pond Street, London, UK), Demosthenes B. Panagiotakos 
(School of Health Science and Education, Department of Nutrition and Dietetics, Harokopio University of 
Athens, Athens, Greece), György Paragh (Department of Internal Medicine, Faculty of Medicine, University 
of Debrecen, Debrecen, Hungary), Daniel Pella (1st Department of Internal Medicine, Faculty of Medicine, 
Pavol Jozef Safarik University, Košice, Slovakia), Peter E. Penson (School of Pharmacy and Biomolecular 
Sciences, Liverpool John Moores University, Liverpool, UK), Zaneta Petrulioniene (Vilnius University Faculty 
of Medicine, Vilnius, Lithuania; Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania), Matteo Pirro 
(Department of Medicine, University of Perugia, Perugia, Italy), Arman Postadzhiyan (Bulgarian Society of 
Cardiology, Medical University of Sofia, Sofia, Bulgaria), Raman Puri (I P Apollo Hospital, New Delhi, India), 
Ashraf Reda (Menoufia University, President of EAVA), Željko Reiner (University Hospital Center Zagreb, 
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